In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dendreon licenses anticoagulant program to Nuvelo

Executive Summary

Nuvelo Inc. (the 2003 merger of Variagenics with Hyseq Pharma) has licensed worldwide development and marketing rights to Dendreon Corp.'s (developing cancer vaccines and treatments) recombinant nematode anticoagulant proteins, including the Phase II drug candidate rNAPc2.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies